Published April 1, 2024 | Version v1
Journal article Open

Abnormal uterine bleeding: The well-known and the hidden face

  • 1. Universidade Federal de Minas Gerais
  • 2. University of Florence
  • 3. University of Edinburgh
  • 4. Université Catholique de Louvain
  • 5. University Federico II of Naples
  • 6. University of Chicago

Description

Abnormal uterine bleeding (AUB) is a bleeding from the uterine corpus that is abnormal in regularity, volume, frequency or duration. It encompasses heavy menstrual bleeding, irregular menstrual bleeding and intermenstrual bleeding, which are common symptoms among women of reproductive age, impacting their overall well-being. Menstruation involves interactions between endometrial epithelial and stromal cells, immune cell influx, and changes in endometrial vasculature. These events resemble an inflammatory response with increased vessel permeability, tissue breakdown, and the arrival of innate immune cells. However, the mechanisms of menstrual cessation are poorly understood. AUB can be related to structural causes (polyp, adenomyosis, leiomyoma, malignancy/hyperplasia) and nonstructural conditions (coagulopathy, ovulatory dysfunction, endometrial, iatrogenic). While transvaginal ultrasound is the primary method for the screening of intracavitary lesions, saline infusion sonohysterography is more accurate to detect endometrial polyps and submucous leiomyomas, while hysteroscopy with biopsy remains the reference method for a definitive diagnosis. The main goals in managing AUB are addressing and correcting the underlying primary cause, if possible, and establishing a regular bleeding pattern or amenorrhea, which can be done with antifibrinolytic agents, progestins, gonadotropin-releasing hormone agonists and antagonists, or surgical interventions, each one with specific indications and limitations. Further research is necessary to assess the effectiveness and the long-term effects of various medical and surgical treatments. Meanwhile, the availability of diagnostic methods such as transvaginal ultrasound and hysteroscopy and the universal distribution of medical treatments for AUB should be prioritized by policymakers to minimize the diagnostic and treatment delay and thus reduce the risk of AUB-related anemia and the need of hysterectomy.

Files

Abnormal-uterine-bleeding.pdf

Files (712.9 kB)

Name Size Download all
md5:339ee965a509c77bef55e5934e7934b4
712.9 kB Preview Download

Additional details

Identifiers

DOI
10.1016/j.jeud.2024.100071
Other
oai:uchicago.tind.io:11522

Funding

Fonds National de la Recherche Scientifique de Belgique (FNRS)
5/4/150/5
National Institutes of Health
R01 ES 028615-01
National Institutes of Health
R01 HD 087417
National Institutes of Health
R01 HD 094378
National Institutes of Health
R01 HD 094380
National Institutes of Health
5U54 MD 007602-32
National Institutes of Health
R01 HD 100367-01
Fundação da Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG)
APQ-03015-21

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Obstetrics and Gynecology